1. Generics Bulletin
  2. >>Business
  3. >>Deals

AmerisourceBergen Strikes $6.5bn Deal For Alliance

Expects To Be Bolstered By Alliance Healthcare’s Generics Assets In Europe

 
• By Dave Wallace

AmerisourceBergen has struck a $6.5bn deal to acquire the majority of the Alliance Healthcare businesseses from Walgreens Boots Alliance, giving it access to Alliance’s generics assets in Europe.

Amerisource_Bergen
AmerisourceBergen has struck a $6.5bn deal for Alliance • Source: Shutterstock

US wholesaler and healthcare services provider AmerisourceBergen has struck a $6.5bn deal with Walgreens Boots Alliance to acquire the majority of the firm’s Alliance Healthcare unit, “one of the largest pharmaceutical wholesalers in Europe,” with a significant UK business. The deal value comprises $6.275bn in cash and 2 million shares of AmerisourceBergen common stock.

Highlighting as part of the deal package Alliance’s Almus range of generics – which it described as “the number one UK generic brand” – as well as the Alvita range of personal care products, AmerisourceBergen also pointed to Alliance’s private-label generics elsewhere

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

CIOMS Welcomes Draft Report Feedback On The Inevitable Future Of AI In Pharmacovigilance

 
• By Urtė Fultinavičiūtė

Pharmacovigilance is a perfect rule-based and manual work-intensive playground for experimenting with AI. While some off-patent drug firms are already exploring new automation tools, regulation is lagging behind, leaving a gap for uncertainty.

Generics Bulletin Explains: The Landscape For Denosumab Biosimilar Competition

 
• By Dave Wallace

One of the biggest biologic loss-of-exclusivity opportunities of the year is almost upon us, as biosimilars developers across the world get ready to launch rivals to Amgen’s denosumab brands Prolia and Xgeva. Generics Bulletin offers a rundown of some of the major contenders and how they view the market.

Trump Order On Domestic Manufacturing Wins Plaudits From Industry

 
• By Dave Wallace

An executive order from US president Donald Trump aimed at incentivizing domestic manufacturing of critical medicines has been welcomed by the US Association for Accessible Medicines.